When will the patent for mounjaro expire?

What happens after patent expiry in the pharmaceutical industry?

When a pharmaceutical company gains market exclusivity for a new product, this is typically due to a lengthy period of research and development, testing, and regulatory approval. The company's patent for the medication grants them a monopoly on the product's sale and manufacture, usually for 20 years from the initial patent filing date.

Who benefits from patent expiry?

The expiry of a pharmaceutical patent means that generic versions of the medication can be manufactured and sold by other companies. This leads to increased competition, reduced prices, and typically, improved patient access to the medication.

Key milestones for Mounjaro [1]
The patent for Eli Lilly's Mounjaro (tirzepatide), filed in 2016, is due to expire soon. According to DrugPatentWatch.com [2], the patents for Mounjaro are set to expire in the United States in 2036. However, these dates are subject to change, and pharmaceutical companies can extend their patents by re-filing and re-patenting different aspects of their products.

Mounjaro's current market dynamics

As Mounjaro is still relatively new to the market, generic versions have yet to enter the scene. However, with patent expiry looming, several pharmaceutical companies are likely to begin developing generic alternatives to the medication.

Competitors and market trends

Several pharmaceutical companies, including Sanofi and Pfizer, are working on developing similar GLP-1 receptor agonist medications. With the expiry of Mounjaro's patent, it's possible that these competitors will gain market share and contribute to increased competition in the type 2 diabetes treatment market.

References:

[1] DrugPatentWatch.com, 'Tirzepatide patents'.
[2] www.drugpatentwatch.com

Note: The information provided is based on publicly available data and patent filings, and is subject to change. The specific patent expiry dates may be adjusted over time.